Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington’s disease

Galectin-3 Enhances Avian H5N1 Influenza A Virus–Induced Pulmonary Inflammation by Promoting NLRP3 Inflammasome Activation

(2018) Yu-Jung Chen et al.   AMERICAN JOURNAL OF PATHOLOGY

Neurogenic inflammation and its role in migraine

(2018) Roshni Ramachandran   Seminars in Immunopathology

Ubiquitination of exposed glycoproteins by SCFFBXO27directs damaged lysosomes for autophagy

(2017) Yukiko Yoshida et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Microglia activation and phagocytosis: relationship with aging and cognitive impairment in the rhesus monkey

(2017) Eli Shobin et al.   GeroScience

NLRP3 inflammasome signaling is activated by low-level lysosome disruption but inhibited by extensive lysosome disruption: roles for K+ efflux and Ca2+ influx

(2016) Michael A. Katsnelson et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Increased Expressions of Plasma Galectin-3 in Patients with Amyotrophic Lateral Sclerosis

(2016) Ling Chen et al.   CHINESE MEDICAL JOURNAL

Galectin-3 Plays an Important Pro-inflammatory Role in the Induction Phase of Acute Colitis by Promoting Activation of NLRP3 Inflammasome and Production of IL-1β in Macrophages

(2016) Bojana Simovic Markovic et al.   Journal of Crohns & Colitis

Microglial immunophenotype in dementia with Alzheimer’s pathology

(2016) Thais Minett et al.   Journal of Neuroinflammation

Manifestation of Huntington’s disease pathology in human induced pluripotent stem cell-derived neurons

(2016) Evgeny D. Nekrasov et al.   Molecular Neurodegeneration

Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors

(2016) Tung-Ju Hsieh et al.   Scientific Reports

NLRP3 inflammasome expression is driven by NF-κB in cultured hepatocytes

(2015) Sorina Georgiana Boaru et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation

(2015) Nobuko Serizawa et al.   LABORATORY INVESTIGATION

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

(2015) Rebecca C Coll et al.   NATURE MEDICINE

Microglia-Secreted Galectin-3 Acts as a Toll-like Receptor 4 Ligand and Contributes to Microglial Activation

(2015) Miguel Angel Burguillos et al.   Cell Reports

Galectin-3 and Plasma Cytokines in Patients With Acute Myocardial Infarction

(2015) A. Ata Alturfan et al.   Labmedicine

HTT-lowering reverses Huntington’s disease immune dysfunction caused by NFκB pathway dysregulation

(2014) Ulrike Träger et al.   BRAIN

Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease

(2014) Han-Yun Hsiao et al.   HUMAN MOLECULAR GENETICS

Galectin-3 Deficiency Reduces the Severity of Experimental Autoimmune Encephalomyelitis

(2014) H.-R. Jiang et al.   JOURNAL OF IMMUNOLOGY

An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex

(2014) Y. Zhang et al.   JOURNAL OF NEUROSCIENCE

Cerebellar abnormalities in Huntington's disease: A role in motor and psychiatric impairment?

(2014) Elin M. Rees et al.   MOVEMENT DISORDERS

Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors

(2014) Andrea Crotti et al.   NATURE NEUROSCIENCE

IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans

(2014) Antonella de Luca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Elevated Galectin-3 Levels in the Serum of Patients With Alzheimer's Disease

(2013) Xuexin Wang et al.   American Journal of Alzheimers Disease and Other Dementias

A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease

(2013) Han-Yun Hsiao et al.   HUMAN MOLECULAR GENETICS

Choosing an animal model for the study of Huntington's disease

(2013) Mahmoud A. Pouladi et al.   NATURE REVIEWS NEUROSCIENCE

Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials

(2013) Nellie Georgiou-Karistianis et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Alpha-Synuclein Induces Lysosomal Rupture and Cathepsin Dependent Reactive Oxygen Species Following Endocytosis

(2013) David Freeman et al.   PLoS One

Huntington's disease: underlying molecular mechanisms and emerging concepts

(2013) John Labbadia et al.   TRENDS IN BIOCHEMICAL SCIENCES

Degeneration of the Cerebellum in Huntington's Disease (HD): Possible Relevance for the Clinical Picture and Potential Gateway to Pathological Mechanisms of the Disease Process

(2012) Udo Rüb et al.   BRAIN PATHOLOGY

Microarray expression analysis and identification of serum biomarkers for Niemann–Pick disease, type C1

(2012) Celine V.M. Cluzeau et al.   HUMAN MOLECULAR GENETICS

Galectin-3 Is Required for Resident Microglia Activation and Proliferation in Response to Ischemic Injury

(2012) M. Lalancette-Hebert et al.   JOURNAL OF NEUROSCIENCE

Deficiency of ATP13A2 Leads to Lysosomal Dysfunction,  -Synuclein Accumulation, and Neurotoxicity

(2012) M. Usenovic et al.   JOURNAL OF NEUROSCIENCE

Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease

(2012) Zhihong Guo et al.   MOVEMENT DISORDERS

NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice

(2012) Michael T. Heneka et al.   NATURE

Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1G93Amouse model of amyotrophic lateral sclerosis

(2012) Bruce J. Lerman et al.   Brain and Behavior

Nuclear translocation of AMPK-α1 potentiates striatal neurodegeneration in Huntington’s disease

(2011) Tz-Chuen Ju et al.   JOURNAL OF CELL BIOLOGY

The fibrosis marker galectin-3 and outcome in the general population

(2011) R. A. de Boer et al.   JOURNAL OF INTERNAL MEDICINE

Development of biomarkers for Huntington's disease

(2011) David W Weir et al.   LANCET NEUROLOGY

Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets

(2011) Mali Jiang et al.   NATURE MEDICINE

Innate and adaptive immunity in amyotrophic lateral sclerosis: Evidence of complement activation

(2011) M. Sta et al.   NEUROBIOLOGY OF DISEASE

GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death

(2010) M. J. Streetly et al.   BLOOD

Responses to Environmental Enrichment Differ with Sex and Genotype in a Transgenic Mouse Model of Huntington's Disease

(2010) Nigel I. Wood et al.   PLoS One

Decreased Diffusivity in the Caudate Nucleus of Presymptomatic Huntington Disease Gene Carriers: Which Explanation?

(2009) M.L. Mandelli et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease

(2008) Maria Björkqvist et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Expanded-Polyglutamine Huntingtin Protein Suppresses the Secretion and Production of a Chemokine (CCL5/RANTES) by Astrocytes

(2008) S.-Y. Chou et al.   JOURNAL OF NEUROSCIENCE